安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Gilead Sciences
Gilead Sciences, a biopharma company, achieves bold ambitions to help make the world a healthier place, leading in HIV, liver disease, cancer inflammation
- Gilead Sciences: Company
Learn about the biopharmaceutical company Gilead Sciences, including mission, vision, values, history, impact, leadership, therapeutic areas and other information
- Medicines - Gilead Sciences
Access the list of approved Gilead therapies across virology including HIV, liver disease including hepatitis and primary biliary cholangitis, oncology inflammation
- Careers at Gilead Sciences
Grow Your Career at Gilead With more than 18,000 employees spanning across 40+ countries on six continents, we have a global workforce dedicated to creating a better, healthier world for everyone Explore Opportunities
- Newsroom | Gilead
This is our global website, intended for visitors seeking information on Gilead’s worldwide business Some content on this site is not intended for people outside the United States Visit our Global Operations page for links to our international corporate websites
- Virology, Inflammation, Oncology Pipeline | Gilead
Through science and innovative partnerships, Gilead expands research and development programs in virology, oncology, inflammation Learn about our pipeline
- Gilead Sciences, Inc. - Investor Relations
At Gilead, we’re committed to creating a healthier world for everyone – no matter the challenges ahead of us For more than 30 years, we’ve pursued the impossible, chased it down, tackled it for answers and surrounded it for a way in
- Yeztugo Lenacapavir Is Now the First and Only FDA Approved HIV . . .
FOSTER CITY, Calif --(BUSINESS WIRE)-- Gilead Sciences, Inc (Nasdaq: GILD) today announced that the U S Food and Drug Administration (FDA) has approved Yeztugo ® (lenacapavir)—the company’s injectable HIV-1 capsid inhibitor—as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing
|
|
|